Abstract
Valproate is a major and well established antiepileptic agent which is in contemporary widespread use in the treatment of the disorder, especially the generalized variety, for which it has become the drug of first choice. It also appears to be finding new uses in the management of a more extensive range of neurological and psychiatric disorders.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Abbott FS, Kassam J, Acheampong A et al. (1986a) Capillary gas chromatography-mass spectrometry of valproic acid metabolites in serum and urine using tert-butyldimethylsilyl derivatives. J Chromatogr 375:285–298
Abbott F, Panesar S, Orr J, Burton R, Farrell K (1986b) Effect of carbamazepine on valproic acid metabolism. Epilepsia 27:591
Abbott FS, Kassam J, Orr JM, Farrell K (1986c) The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther 40:94–100
Adkison KD, Shen DD (1996) Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J Pharmacol Exp Ther 276:1189–1200
Adkison KDK, Ojemann GA, Rapport R, Dills RL, Shen DD (1995) Distribution of unsaturated metabolites of valproate in human and rat brain—pharmacologic relevance? Epilepsia 36:772–782
Anderson GD, Acheampong AA, Wilensky AJ, Levy RH (1992) Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 33:736–742
Anderson GD, Gidal BE, Hendryx RJ, Awan AB, Temkin NR, Wilensky AJ, Winn HR (1994) Decreased plasma protein binding of valproate in patients with acute head trauma. Br J Clin Pharmacol 37:559–562
Anderson GD, Yau MK, Gidal BE et al. (1996) Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 60:145–156
Anderson GD, Awan AB, Adams CA, Temkin NR, Winn HR (1998) Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury. Br J Clin Pharmacol 45:101–105
Baillie TA, Sheffels PR (1995) Valproic acid: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn, Raven Press, New York
Bernus I, Dickinson RG, Hooper WD, Eadie MJ (1994) Inhibition of phenobarbitone N-glucosidation by valproate. Br J Clin Pharmacol 38:411–416
Bowdle TA, Patel IH, Levy RH, Wilensky AJ (1980) Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 28:486–492
Carrigan PJ, Brinker DR, Cavanaugh JH, Lamm JE, Cloyd JC (1990) Absorption characteristics of a new valproate formulation of divalproex sodium-coated particles in capsules (DepakoteTM Sprinkle). J Clin Pharmacol 30:743–747
Cavanaugh JH, Granneman R, Lamm J, Linnen P, Chun AHC (1997) Effect of food on the bioavailability of a controlled-release formulation of depakote under multiple-dose conditions. Epilepsia 38:S54
Cloyd JC, Kriel RL (1981) Bioavailability of rectally administered valproic acid syrup. Neurology 31:1348–1352
Cramer JA, Mattson RH, Bennett DM, Swick CT (1986) Variable free and total valproic acid concentrations in sole- and multidrug therapy. Ther Drug Monit 8:411–415
Dencker L, Nau H, D’Argy R (1990) Marked accumulation of valproic acid in embryonic neuroepithelium of the mouse during early organogenesis. Teratology 41:699–706
Fanello RG, Varasi M, Smith MC (1995) Valproic acid: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York
Fischer JH, Barr AN, Paloucek FP, Dorociak JV, Spunt AL (1988) Effect of food on the serum concentration profile of enteric-coated valproic acid. Neurology 38:1319–1322
Franceschetti S, Hamon B, Heineman U (1986) The action of valproate on spontaneous epileptiform activity in the absence of synaptic transmission on evoked changes in [Ca++] and [K+] in the hippocampal slice. Brain Res 386:1–11
Frey H-H, Löscher W (1978) Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology 17:637–642
Gale K (1988) Progression and generalization of seizure discharge: anatomical and neurochemical substrates. Epilepsia 29:S15–S34
Gean P-W, Hung C-C, Hung C-R, Tsai J-J (1994) Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 33:333–336
Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, Santo Buelga D, Dominquez-Gil A (1993) Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharmacol Ther 18:191–197
Granneman GR, Marriott TB, Wang SI, Sennello LT, Hagen NS, Sonders RC (1984) Aspects of the dose-dependent metabolism of valproic acid. In: Levy RH, Pitlick WH, Eichelbaum M, Meijer J (eds) Metabolism of antiepileptic drugs. Raven Press, New York, pp 97–104
Green MD, Bishop WP, Tephley TR (1995) Expressed human UGT-1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23:299–302
Hooper WD, Franklin ME, Glue P, Banfield CR, Radwanski E, McLaughlin DB, McIntyre ME, Dickinson RG, Eadie MJ (1996) Effect of falbamate on valproic acid disposition in healthy volunteers: Inhibition of β-oxidation. Epilepsia 37:91–97
Hurst S, Labroo R, Carlson S, Mather G, Levy R (1997) In vitro inhibition profile of valproic acid for cytochrome P450. International Society for the Study of Xeno-biotics. Hilton Head, South Carolina (abstract):64
Kerr BM, Rettie AW, Eddy AC, Loiseau P, Guyot M, Wilensky AJ, Levy RH (1989) Inhibition of human liver microsomal epoxide hydrolase by valproate and val-promide: in vitro/in vivo correlation. Clin Pharmacol Ther 46:82–93
Klotz U, Rapp T, Müller WA (1978) Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 13:55–60
Ko GY-PL, Brown-Croyts LM, Teyler TJ (1997) The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-DPSP, and GABA-IPSP in the rat hippocampus. Brain Res Bull 42:297–302
Kondo T, Otani K, Hirano T, Kaneko S, Fukushima Y (1990) The effects of phenytoin and carbamazepine on serum concentration of mono-unsaturated metabolites of valproic acid. Br J Clin Pharmacol 29:116–119
Kondo T, Kaneko S, Otani K et al. (1992) Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia 33:172–177
Lertora J, Rege A, Greenspan D, Akula S (1994) Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with immunodeficiency virus. Clin Pharmacol Ther 56:272–278
Leveil V, Naquet R (1977) A study of the action of valproic acid on the kindling effect. Epilepsia 18:229–234
Levy RH (1980) CSF and plasma pharmacokinetics: relationship to mechanisms of action as exemplified by valproic acid in monkey. In: Lockard J, Ward A (eds) Epilepsy: a window to brain mechanisms. Raven Press, New York 11:191–200
Levy RH, Shen DD (1995) Valproic acid: absorption, distribution, and excretion. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York
Levy RH, Cenraud B, Loiseau P et al. (1980) Meal-dependent absorption of enteric-coated sodium valproate. Epilepsia 21:273–280
Levy RH, Moreland TA, Morselli PL, Guyot M, Brachet-Liermain A, Loiseau P (1984) Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia 25:338–345
Levy RH, Rettenmeier AW, Anderson GD et al. (1990) Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 48:225–235
Loiseau P, Brachet-Liesmain A, Guyot M, Morselli P (1982) Diurnal variations in steady state plasma concentrations of valproic acid in epileptic patients. Clin Pharm 7:544–552
Löscher W (1993) Effects of the antieplieptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 18:485–502
Löscher W, Nau H (1984) Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences. Arch Int Pharmacodyn Ther 270:192–202
Löscher W, Vetter M (1984) Drug-induced changes in GABA content of nerve endings in 11 rat brain regions: correlation to pharmacological effects. Neurosci Lett 47:325–331
Löscher W, Fisher JE, Nau H, Hönack D (1988) Marked increase in anticonvulsant activity but decrease in wet-dog shake behaviour during short-term treatment of amygdala-kindled rats with valproic acid. Eur J Pharmacol 150:221–232
Löscher W, Hönack D, Nolting B, Fassbender CP (1991) Trans-2-en-valproate: reevaluation of its anticonvulsant efficacy in standardized seizure models in mice, rats and dogs. Epilepsy Res 9:195–210
McLean MJ, MacDonald RL (1986) Sodium valproate, but not ethosuximide, produces use and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 237:1001–1011
Naora K, Shen DD (1995) Mechanism of valproic acid uptake by isolated rat brain microvessels. Epilepsy Res 22:97–106
Nau H, Krauer B (1986) Serum protein binding of valproic acid in fetus-mother pairs throughout pregnancy: correlation with oxytocin administration and albumin and free fatty acid concentrations. J Clin Pharmacol 26:215–221
Nowack WJ, Johnson RN, Englander RN, Hanna GR (1979) Effects of valproate and ethosuximide on thalamocortical excitability. Neurology 29:96–99
Philbert A, Dam M (1982) The epileptic mother and her child. Epilepsia 23:85–99
Pisani F, Caputo M, Fazio A et al (1990) Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia 31:339–342
Piasse J-C, Revol M, Chabert G, Ducerf F (1979) Neonatal pharmacokinetics of valproic acid. In: Schaaf D, van der Kleijn E (eds) Progress in clinical pharmacy. Else-vier/North-Holland Biomedical Press, Amsterdam, pp 247–252
Pollack GM, Shen DD (1985) A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J Pharmacol Methods 13:135–146
Rettenmeier AW, Prickett KS, Gordon WP, Bjorge SM, Chang SL, Levy RH, Baillie TA (1985) Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos 13:81–96
Robbins DK, Wedlund PJ, Kuhn R, Baumann RJ, Levy RH, Chang S-L (1990) Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine. Br J Clin Pharmacol 29:759–762
Roberts D, Easter D, O’Bryan-Tear G (1996) EpilimR chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. Biopharm Drug Dispos 17:175–182
Rohlfs A, Rundfeldt C, Koch R, Löscher W (1996) A comparison of the effects of valproate and its major active metabolite E-2-en-valproate on single unit activity of sustantia nigra pars reticulata neurons in rats. J Pharmacol Exp Ther 277:1305–1314
Samara E, Granneman R, Achari R, Locke C, Cavanaugh J, Boellner S (1997a) Bioavailability of a controlled-release formulation of depakote. Epilepsia 38:S102
Samara EE, Granneman RG, Witt GF, Cavanaugh JH (1997b) Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. J Clin Pharmacol 37:442–450
Scism JL, Powers KM, Artru AA, Shen DD (1996) The effect of probenecid on extracellular and intracellular compartmentation of valproic acid in the rabbit brain as determined by microdialysis. Pharm Res 13:S456
Semmes RLO, Shen DD (1991) Comparative pharmacodynamics and brain distribution of E-Δ2-valproate and valproate in rats. Epilepsia 32:232–241
Shen DD, Pollack GM, Cohen ME, Duffner P, Lacey D, Ryan-Dudek P (1984) Effect of age on the serum metabolite pattern of valproic acid. Epilespsia 25:674
Shen DD, Ojemann GA, Rapport RL, Dills RL, Friel PN, Levy RH (1992) Low and variable presence of valproic acid in human brain. Neurology 42:582–585
Snead OC III, Miles MV (1985) Treatment of status epilepticus in children with rectal sodium valproate. J Pediatr 106:323–325
Sugimoto T, Muro H, Woo M, Nishida N, Murakami K (1996) Metabolite profiles in patients on high-dose valproate monotherapy. Epilepsy Res 25:107–112
Swinyard EA (1964) The pharmacology of dipropylacetic acid sodium with special emphasis on its effects on the central nervous system. Thesis, University of Utah, College of Pharmacy, Salt Lake City, pp 1–25
Ticku MK, Davis WC (1981) Effect of valproic acid on H-diazepam and H-dihydropi-crotoxin in binding sites at the benzodiazepine-GABA receptor-ionophore complex. Brain Res 223:218–222
Vajda FJE, Mihaly GW, Miles JL, Donnan GA, Bladin PF (1978) Rectal administration of sodium valproate in status epilepticus. Neurology 28:897–899
Wagner ML, Graves NM, Leppik IE, Remmel RP, Shumaker RC, Ward DL, Perhach JL (1994) The effect of felbamate on valproic acid disposition. Clin Pharmacol Ther 56:494–502
Wikinski SI, Acosta GB, Rubio MC (1996) Valproic acid differs in its in vitro effect on glutamic acid decarboxylase activity in neonatal and adult rat brain. Gen Pharmacol 27:635–638
Willmore JL, Shu V, Wallin B, and the M88–194 Study Group (1996) Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. Neurology 46:49–53
Yoshiyama Y, Nakano S, Ogawa N (1989) Chronopharmacokinetics study of valproic acid in man: comparison of oral and rectal administration. J Clin Pharmacol 29:1048–1052
Yuen AWC, Land G, Weatherley BC, Peck AW (1992) Sodium valproate acutely inhibits lamotrigene metabolism. Br J Clin Pharmacol 33:511–513
Zeise ML, Kasparow S, Zieglgänsberger W (1991) Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 544:345–348
Zhang Y-F, Gibbs JW, Coulter DA (1996) Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: valproic acid, clonazepam, and α-methyl-α-phenylsuccinimide. Epilepsy Res 23:37–53
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Shen, D.D., Levy, R.H. (1999). Valproate. In: Eadie, M.J., Vajda, F.J.E. (eds) Antiepileptic Drugs. Handbook of Experimental Pharmacology, vol 138. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60072-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-60072-2_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64244-9
Online ISBN: 978-3-642-60072-2
eBook Packages: Springer Book Archive